HC Wainwright Issues Negative Estimate for Clene Earnings

Clene Inc. (NASDAQ:CLNN) – Stock analysts at HC Wainwright lowered their Q3 2026 earnings estimates for Clene in a research report issued on Friday, August 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.48) for the quarter, down from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Clene’s current full-year earnings is ($1.58) per share. HC Wainwright also issued estimates for Clene’s Q4 2026 earnings at ($0.41) EPS and FY2026 earnings at ($2.17) EPS.

Clene (NASDAQ:CLNN) last released its quarterly earnings results on Friday, August 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.71). The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.06 million.

A number of other research analysts have also recently commented on CLNN. Weiss Ratings upgraded Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Monday, May 4th. Finally, Roth Capital restated a “buy” rating on shares of Clene in a report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.25.

Clene Stock Performance

Clene stock opened at $4.20 on Tuesday. The company has a market capitalization of $53.68 million, a PE ratio of -1.20 and a beta of 0.96. Clene has a fifty-two week low of $3.64 and a fifty-two week high of $13.50. The firm has a 50 day moving average price of $5.58 and a 200 day moving average price of $5.63.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SymBiosis Capital Partners LLC purchased a new stake in shares of Clene during the 4th quarter worth $4,523,000. Scoggin Management LP increased its holdings in Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares during the last quarter. Ensign Peak Advisors Inc raised its stake in Clene by 668.6% in the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after buying an additional 99,481 shares in the last quarter. PEAK6 LLC acquired a new stake in Clene in the fourth quarter valued at $294,000. Finally, State Street Corp lifted its holdings in Clene by 138.4% during the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after buying an additional 17,300 shares during the last quarter. Institutional investors and hedge funds own 23.28% of the company’s stock.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).